Ardelyx

ARDX · NASDAQ

$3.21+$0.12 (+3.88%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $3.09

ARDX analyst rating

BuyConsensus of 7 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy7
Hold0
Underperform0
Sell0

12-month price target · 13 analysts

Average $13.23 (+312.2% upside)

Low: $8.08
Now: $3.21
High: $18.90

Upgrades and downgrades

The latest rating actions, newest first

ARDX analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Wedbush	Aug 19, 2026	Maintains	Outperform	$9.00	40%
Wedbush	Aug 18, 2026	Maintains	Outperform	$9.00	40%
Piper Sandler	Aug 17, 2026	Maintains	Overweight	$16.00 → $15.00	51%
Citigroup	Aug 10, 2026	Maintains	Buy	$14.00 → $11.00	42%
TD Cowen	Aug 7, 2026	Maintains	Buy	$13.00 → $10.00	27%
BTIG	Aug 7, 2026	Maintains	Buy	$17.00 → $14.00	34%
Ladenburg Thalmann	Jun 16, 2026	Initiates	Buy	$16.00	36%
Wedbush	Feb 23, 2026	Maintains	Outperform	$19.00	40%
HC Wainwright & Co.	Feb 20, 2026	Maintains	Buy	$10.00 → $18.00	47%
BTIG	Feb 20, 2026	Maintains	Buy	$17.00	34%

The case for and against

Updated Oct 15, 2026

Bull case

Ardelyx is supported by a differentiated tenapanor franchise that remains the only sodium transport inhibitor approved for IBS-C and phosphate reduction in dialysis CKD, giving it two large markets with substantial unmet need and limited near-term competition. Despite 2Q26 reimbursement headwinds and an unexpected leadership transition, Ibsrela still grew 33% y/y to $86.2M while Xphozah rose 27% y/y to $31.9M, and management reaffirmed $110M-$120M of FY26 Xphozah revenue with a path to profitability in 2027. The company’s outlook is further strengthened by >95% gross margins, $281.8M in cash and equivalents at the end of 2Q26, an expanded sales and reimbursement effort, and optionality from CIC and broader IBS-C growth opportunities.

Bear case

Ardelyx is exposed to meaningful regulatory risk because its accelerated approval strategy could still require additional data, longer studies, or narrower labels that weaken commercial traction. Its outlook is further pressured by reimbursement uncertainty, since changes in pricing structures could reduce access and revenue potential for IBSRELA and XPHOZAH. Commercial execution risk remains high, and intensifying competition from generic players and established companies such as AMGN, OPKO, Shield Therapeutics, and AKBA could limit adoption and make sustained growth difficult.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.